Press release
Rottenstein Law Group Learns of Research Showing SSRIs Are Linked to Preterm Births
The Rottenstein Law Group, which represents clients with claims stemming from birth defects caused by the Selective Serotonin Reuptake Inhibitor (SSRI) Zoloft, has learned of research showing that the fetuses of pregnant women who took SSRIs to treat their depression were twice as likely to be born preterm as the fetuses of both not-depressed pregnant women and the fetuses of women with depression that was left untreated.The study that produced this finding was published online on March 12, 2012, in the Archives of General Psychiatry. Using ultrasound equipment, the study’s researchers tracked the development of the fetuses of more than 7,600 pregnant women, all of whom fell into one of three groups: (1) not-depressed, (2) depressed and taking SSRIs during pregnancy, or (3) depressed but not taking SSRIs (i.e., suffering from untreated depression).
The study was also one of the first to track the effect of SSRIs on fetal head development, an important touchstone since small head size in infants has been linked to behavioral problems and poor cognitive performance later in life. The fetuses of the study subjects who took SSRIs to treat their depression were significantly more likely to have delayed head growth than the fetuses of their not-depressed counterparts. The fetuses of women with untreated depression were significantly more likely to have reduced head growth, too, however.
“The researchers note that although treating depression during pregnancy is highly important, ‘high-quality studies with good controls’ about the effect of SSRIs on an unborn child's health ‘are sparse,’” writes a journalist in a Medscape.com article describing the study’s results.
The Medscape .com journalist further quotes the study’s researchers: “‘Thus, trying to balance the possible negative consequences of untreated maternal depression with the unknown potential negative consequences of SSRIs remains an open debate,’ they write.”
RLG’s Zoloft Lawsuit Information Center, at www.zoloftsertralinebirthdefects.com, has features that allow for easy sharing, including links for automatic posting on Facebook and Twitter, specifically to enable visitors to spread the word about Zoloft and the dangers of the drug. The Rottenstein Law Group, a personal injury firm, encourages visitors to link to its sites from their own blogs and websites to spread information about defective medical products and dangerous drugs.
The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions. The firm was recently founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients in consumer product injury, mass tort, and class action lawsuits in a compassionate manner. http://www.rotlaw.com
1259 Veeder Drive, Hewlett, NY 11557
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rottenstein Law Group Learns of Research Showing SSRIs Are Linked to Preterm Births here
News-ID: 215535 • Views: …
More Releases for SSRI
Selective Serotonin Reuptake Inhibitors Market Emerging Trend, Industry Demand, …
The global selective serotonin reuptake inhibitors (SSRI) market is expected to grow at a significant CAGR during the forecast period (2024-2031). The prevalence of depression is on the rise throughout the globe. Depression and serotonin levels are linked as depression is indicated by a decrease in serotonin levels. As a result, pharmaceutical companies have developed SSRIs that block 5-hydroxytryptamine (5-HT) reuptake transporters to raise serotonin levels in the synaptic cleft.…
Selective Serotonin Reuptake Inhibitors Market Comprehensive Insight by Growth R …
Selective Serotonin Reuptake Inhibitors Market is expected to grow at a significant CAGR during the forecast period. The prevalence of depression is on the rise throughout the globe. Depression and serotonin levels are linked as depression is indicated by a decrease in serotonin levels. As a result, pharmaceutical companies have developed SSRIs that block 5-hydroxytryptamine (5-HT) reuptake transporters to raise serotonin levels in the synaptic cleft. In addition, SSRIs are…
Selective Serotonin Reuptake Inhibitors Market: Analysis Report, Share, Trends a …
The global selective serotonin reuptake inhibitors (SSRI) market is expected to grow at a significant CAGR during the forecast period (2021-2027). The prevalence of depression is on the rise throughout the globe. Depression and serotonin levels are linked as depression is indicated by a decrease in serotonin levels. As a result, pharmaceutical companies have developed SSRIs that block 5-hydroxytryptamine (5-HT) reuptake transporters to raise serotonin levels in the synaptic cleft.…
SSRI Market 2026|Major Manufacturers-Pfizer, Eli Lilly, Merck, Alexion, Allergan …
Global SSRI Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Increasing incidences of allergic conditions that trigger the hyper production of histamine will propel the market growth in the forecast period. However, increased preference for complementary and alternative medicine (CAM) may restrain the market growth.
For Sample Copy…
Antidepressant Drugs Market : Exploration on Eminent Players | Allergan, Alkerme …
Antidepressant Drugs Market size is projected to experience significant growth from 2018 to 2024.
Increasing stress levels, depression, elevated alcoholism and crime rates in the younger populations are foremost driving factors for increased use of antidepressant drugs. Tremendous diagnosis of cancer and tumor patients that increases the incidence of depression among cancer patients will potentially grow antidepressants market.
Request In-depth table of contents @ https://www.gminsights.com/request-toc/upcoming/2505
Growing geriatric population drives…
Antidepressant Drugs Market : Study on Key Players | Allergan, Alkermes, AstraZe …
Antidepressant Drugs Market size is projected to experience significant growth from 2018 to 2024.
Increasing stress levels, depression, elevated alcoholism and crime rates in the younger populations are foremost driving factors for increased use of antidepressant drugs. Tremendous diagnosis of cancer and tumor patients that increases the incidence of depression among cancer patients will potentially grow antidepressants market.
Growing geriatric population drives anti-depressants market. Elderly population is prone…